35 results about "Antibody receptor" patented technology

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.

The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

This invention relates to whole antibodies of neutral isotype having specificity for E-selectin, process for their preparation (using vectors), pharmaceutical compositions containing them, and their use in therapy and diagnosis. Said antibodies are variants of natural antibodies altered in the Fc region, especially in the CH2 domain, so that the interactions with antibodies Fc receptors and complement are very low.

A fusion protein for delivery of a wide variety of agents to a cell via antibody-receptor-mediated endocytosis comprises a first segment and a second segment: the first segment comprising a variable region of an antibody that recognizes an antigen on the surface of a cell that after binding to the variable region of the antibody undergoes antibody-receptor-mediated endocytosis, and, optionally, further comprises at least one domain of a constant region of an antibody; and the second segment comprising a protein domain selected from the group consisting of avidin, an avidin mutein, a chemically modified avidin derivative, streptavidin, a streptavidin mutein, and a chemically modified streptavidin derivative. Typically, the antigen is a protein. Typically, the protein antigen on the surface of the cell is a receptor such as a transferrin receptor-or an insulin receptor. The invention also includes an antibody construct incorporating the fusion protein that is either a heavy chain or a light chain together with a complementary light chain or heavy chain to form an intact antibody molecule. The invention further includes targeting methods and screening methods.

The invention provides a tilted fiber Bragg grating (TFBG)-based surface plasmon resonance (SPR) biosensor which is characterized by comprising a broadband light source (1), a polarizing beam splitter prism (2), an optical isolator (3), a TFBG (4) coated with gold / biological adsorption layer, a reaction tank (5) and a spectrum analyzer (6), wherein the broadband light source (1) and the polarizing beam splitter prism (2) are connected with each other by virtue of an optical fiber and then are connected with the optical isolator (3); and the TFBG (4) coated with the gold / biological adsorption layer is arranged in the reaction tank (5) and is connected with the optical isolator (3) and the spectrum analyzer (6). The TFBG serves as a sensing part, and compared with a common optical fiber SPR sensor, the SPR biosensor disclosed by the invention has the advantages that the wavelength of the light source is simply changed, any mode of emitting light to a fiber core-cladding layer at different angles can be almost generated, resonance is easily realized, the resonance strength is greatly improved, and the information detection capacity is greatly enhanced; the sensitivity of the detector is greatly improved, and the detector can be used for detecting change of concentration of a solution with small biological molecules; and moreover, bovine serum albumin is adopted by the biological adsorption layer, and thus the interaction process between protein-protein and antibody-receptor biological proteins can be efficiently and accurately monitored.

This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Described are methods for treating, preventing, or reducing the risk of, miscarriages, especially recurrent miscarriages. The methods comprise administering to a female subject a therapeutic agent that modulates the activity or binding of components of the complement system, together with a pharmaceutically acceptable carrier. For example, the therapeutic agent can be a C3-convertase inhibitor, an antibody against C5, an antagonist of the C5a receptor, or an antibody against factor B or factor D. Screening methods for agents that can prevent or reduce the risk of miscarriages, especially recurrent miscarriages, are also described.

The invention discloses a method for improving the sensitivity of competitive immunoassay. The method is mainly characterized in that a micromolecular substance to be detected is fully reacted with an antibody / receptor firstly and then reacted with a second molecule which participates in competition and is located on a solid phase in a short time, thus the sensitivity of the competitive immunoassay can be greatly improved. The method disclosed by the invention has the advantages of simplicity in operation, low cost, no need of expensive equipment and professional technicians, high sensitivity, and applicability to a plurality of immunoassay methods.

The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.

The invention relates to a homogeneous immunoassay method, in which at least two detection regions are used, in one detection region, it is determined whether a first composite formed by a donor-antibody to be detected-receptor exists or not, in the other detection region, it is determined whether a second composite formed by a donor-antigen to be detected-receptor exists or not. Wherein the donorcan generate singlet oxygen in an excited state, and the receptor can react with the singlet oxygen to generate a detectable signal. The method solves the problems of HOOK effect of a high-concentration sample and low detection sensitivity of a low-concentration sample in antigen-antibody one-step detection. Meanwhile, the method also solves the problem that whether a positive result is antibodypositive or antigen positive cannot be distinguished during antigen-antibody combined detection. The method provided by the invention is especially suitable for combined detection of HIV antigen and antibody.

The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis.

The invention relates to the field of biological detection and discloses a detection device and a detection method of a large class of beta-agonists drugs by applying an immune chromatography technology. According to the invention, an antibody / receptor which is reacted with a large class of the beta-agonists drugs is used for preparing an immune chromatography test strip to realize the simultaneous detection of a large class of the beta-agonists drugs. Compared with the prior art, the detection on a large class of the beta-agonists drugs for one time can be realized, the detection cost is low and the method is convenient and fast.

This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

An engineered immune cell that does not express a T cell receptor (TCR) and comprises a CD3 antibody receptor complex. The invention also relates to a pharmaceutical composition containing the modified immune cell and a bispecific antibody, and an application of the pharmaceutical composition in preparation of medicines.

The invention relates to a chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR comprises an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system. The invention relates to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid molecule comprising a sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. In one embodiment, the autoantigen encoded by the nucleic acid sequence comprises or consists of an N- methyl-D-aspartate receptor (NMDAR), or one or more NMDAR fragments. The invention further relates to the chimeric autoantibody receptor (CAAR) protein of the invention, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR) of the invention, a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and the use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and / or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and / or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

Chimeric autoantibody receptors (CAARs) can include separate signaling and recognition constructs that are able to bind ligands that target autoantigens made of conventional amino acids, non-conventional amino acids, carbohydrates, or nucleic acids. Additionally, the present disclosure describes cells modified to express such constructs and the use of such constructs and / or cells in the treatment of autoimmune disease.

The present disclosure provides a chimeric autoantibody receptor (CAAR) that is specific for an autoantibody-based B cell receptor (BCR), wherein the autoantibody is specific for nAChR. The disclosure also provides compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising the polynucleotides encoding the CAAR, engineered cells comprising the CAAR, and methods of using the same.

The present invention relates to a homogeneous immunoassay method, which comprises at least two detection areas, in one detection area it is judged whether there is a first complex formed by donor-to-be-detected antibody-acceptor, and in another detection area Judging whether there is a second complex formed by donor-antigen-receptor; wherein, the donor can generate singlet oxygen in an excited state, and the acceptor can react with singlet oxygen to produce detectable signal of. The method solves the problem of HOOK effect of high-concentration samples and low detection sensitivity of low-concentration samples in the one-step detection of antigen and antibody. At the same time, the method also solves the problem that the positive result cannot be distinguished from antibody positive or antigen positive in combined detection of antigen and antibody. The method of the present invention is especially suitable for combined detection of HIV antigen and antibody.

The present disclosure provides a chimeric anti-drug antibody receptor (CADAR) having specificity for an anti-drug antibody based B cell receptor (BCR), wherein the anti-drug antibody is induced by a therapeutic anti-TNF-alpha monoclonal antibody. The disclosure also provides compositions comprising the CADAR, polynucleotides encoding the CADAR, vectors comprising the polynucleotides encoding the CADAR, engineered cells comprising the CADAR, and methods of using the same.